Status:
COMPLETED
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
Lead Sponsor:
GlaxoSmithKline
Conditions:
Nausea and Vomiting, Chemotherapy-Induced
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- healthy
- female subjects who cannot become pregnant
- able to swallow and keep down oral medication
- can understand and follow the protocol requirements and instructions
- Exclusion criteria:
- smokes at least 4 packs per day in the past 12 months
- use of prescription or non-prescription drug(s)
- herbal or dietary supplements or vitamins with 14 days prior to first dose of study medication
- a clinically relevant abnormality medical condition or circumstance making the subject unsuitable for the study per the study doctor
- blood donation in excess of 1 pint within 56 days before dosing of medication
- iron deficient
- history or drug allergy of study medication
- history of drug or alcohol abuse or dependency within the past 6 months
- subjects cannot use any nicotine-containing products within the last 6 months
- positive for HIV, Hepatitis B or C
- active peptic ulcer disease
- uncontrolled nausea and vomiting
- active infection
- heart failure
- female who is lactating
- female who has a positive pregnancy test
Exclusion
Key Trial Info
Start Date :
November 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 5 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00405080
Start Date
November 11 2006
End Date
January 5 2007
Last Update
September 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Tacoma, Washington, United States, 98418